Per Björkman

Prof. Dr. Per Björkman

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
ANAnna C Nilsson
Anna C Nilsson
PBPer Björkman
Per Björkman
KPKenneth Persson
Kenneth Persson
Diagnosis of Mycoplasma pneumoniae (MP) infection is traditionally based on serology, which may require more than two weeks for diagnostic antibodies to develop. PCR-based methods offer earlier diagnosis. During a community outbreak of MP infection, we compared semi-nested and real-time PCR of oropharyngeal swabs with serology for diagnosis of MP infection at different time points after disease onset. PCR-positive individuals were followed longitudinally to assess the persistence of MP DNA in throat secretions. We also studied carriage of MP among household contacts and school children.

25 February 2010 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
ANAnna C Nilsson
Anna C Nilsson
PBPer Björkman
Per Björkman
CWChristina Welinder-Olsson
Christina Welinder-Olsson
AWAnders Widell
Anders Widell
KPKenneth Persson
Kenneth Persson
Disease severity in Mycoplasma pneumoniae (MP) infection could potentially be related to bacterial factors such as MP genotype (MP1 or MP2; distinguished by different adhesions proteins) or bacterial load in airway secretions. We have compared these parameters in patients who were hospitalized for MP pneumonia, with outpatients with mild MP disease.

10 October 2014 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
TBT. T. Balcha
T. T. Balcha
SSS. Skogmar
S. Skogmar
ESE. Sturegård
E. Sturegård
TST. Schön
T. Schön
NWN. Winqvist
N. Winqvist
PBPer Björkman
Per Björkman
Background. The World Health Organization (WHO) tuberculosis (TB) symptom screening instrument (WHO-TB) can ide.jpegy human immunodeficiency virus (HIV)-infected individuals at low risk of tuberculosis (TB); however, many patients report WHO-TB symptoms and require further TB investigations. We hypothesized that further clinical scoring could classify subjects with a positive WHO-TB screening result (WHO-TB+) for the likelihood of TB. Methods. HIV-infected adults eligible to initiate antiretroviral therapy (ART) were recruited and prospectively followed at 5 Ethiopian health centers. Irrespective of symptoms, all participants underwent sputum bacteriological testing for TB. Symptoms, physical findings, hemoglobin, and CD4 cell count results were compared between subjects with and those without bacteriologically confirmed TB. Variables associated with TB in WHO-TB+ individuals were used to construct a scoring algorithm with multiple logistic regression analysis. Results. Among 812 participants, 137 (16.9%) had TB. One hundred fifty-nine persons (20%) had a negative WHO-TB screen, 10 of whom had TB (negative predictive value [NPV], 94% [95% confidence interval {CI}, 90%–97.5%]). For WHO-TB+ subjects, the following variables were independently associated with TB, and were assigned 1 point each in the clinical scoring algorithm: cough, Karnofsky score ≤80, mid-upper arm circumference <20 cm, lymphadenopathy, and hemoglobin <10 g/dL. Among subjects with 0–1 points, 20 of 255 had TB (NPV, 92% [95% CI, 89%–95%]), vs 19 of 34 participants with ≥4 points (positive predictive value, 56% [95% CI, 39%–73%]). The use of WHO-TB alone ide.jpegied 159 of 784 (20%) with a low risk of TB, vs 414 of 784 (53%) using WHO-TB followed by clinical scoring (P< .001). The difference in proportions of confirmed TB in these subsets was nonsignificant (6.3% vs 7.2%; P= .69). Conclusions. Clinical scoring can further classify HIV-infected adults with positive WHO-TB screen to assess the risk of TB, and would reduce the number of patients in need of further TB investigations before starting ART. Clinical Trials Registration. NCT01433796.

1 July 2018 in Drug and Alcohol Dependence
Verified
Journal Article
Open access
AÅAda Åhman
Ada Åhman
AJAnna Jerkeman
Anna Jerkeman
MBMarianne Alanko Blomé
Marianne Alanko Blomé
PBPer Björkman
Per Björkman
Anders C HåkanssonAnders C Håkansson
Anders C Håkansson
Abuse of amphetamines is a worldwide problem with around 34 million users, and amphetamine is commonly used by people who inject drugs (PWID). Despite this, there is relatively little research on mortality and cause of death among people who use amphetamines primarily. The present study aimed to examine mortality and causes of death among people who inject amphetamine, and compare these results to the general population. This retrospective cohort study was based on data from The Malmö Needle Exchange Program in Sweden (MNEP) and on data from The Swedish National Cause of Death Register. Participants in the MNEP, between 1987 and 2011, with registered national identity number and amphetamine as their primary drug of injection use, were included in the study. Standardized mortality ratios (SMR) was calculated for overall mortality and categories of causes of death. 2019 individuals were included (mean follow-up-time 13.7 years [range 0.02-24.2 years], a total of 27,698 person-years). Of the 448 deceased, 428 had a registered cause of death. The most common causes of death were external causes (n = 162, 38%), followed by diseases of the circulatory system (n = 67, 16%). SMR were significantly elevated (8.3, 95% CI [7.5-9.1]) for the entire study population, and for every category of causes of death respectively. People injecting amphetamine as a primary drug were found to have significantly elevated mortality compared with the general population, with high rates of both external and somatic causes of death.

17 May 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HBHanna Brattgård
Hanna Brattgård
PBPer Björkman
Per Björkman
PNPiotr Nowak
Piotr Nowak
CTCarl Johan Treutiger
Carl Johan Treutiger
MGMagnus Gisslén
Magnus Gisslén
OEOlof Elvstam
Olof Elvstam
Objective: Low-level viraemia (LLV) occurs in some people with HIV (PWH) receiving antiretroviral therapy (ART) and has been linked to inferior treatment outcomes. We investigated factors associated with LLV in a nationwide cohort of Swedish PWH starting ART. Methods: Participants were identified from the InfCareHIV register, with the following inclusion criteria: ART initiation 2006–2017, age >15 years, ≥4 viral load (VL) results available and no documented treatment interruptions or virologic failure (≥2 consecutive VL ≥200 copies/ml) during follow-up. Starting from 6 months after ART initiation, participants were followed for 24 months and categorised as viral suppression (VS; VL <50 copies/ml) or LLV (≥2 consecutive VL 50–199 copies/ml). We analysed the association between the following factors and LLV using multivariable logistic regression: sex, age, pre-ART VL and CD4 count, ART regimen, country of birth, HIV-1 subtype and transmission category. Results: Among 3383 participants, 3132 (92.6%) had VS and 251 (7.4%) had LLV. In univariable analyses, factors associated with LLV were male sex, higher age, lower pre-ART CD4 count, higher pre-ART VL and ART regimen. After adjustment, the following factors were associated with LLV (adjusted odds ratio; 95% confidence interval): male sex (1.6; 1.1–2.3), higher pre-ART VL (2.7; 2.2–3.3), pre-ART CD4 count <200 cells/μl (1.6; 1.2–2.2), protease inhibitor (PI)-based regimen (1.5; 1.1–2.1), non-standard ART (2.4; 1.0–5.5) and injecting drug use (2.0; 1.1–3.7). Conclusion: Among Swedish PWH, LLV during ART was associated with markers of HIV disease severity before starting ART, male sex, injecting drug use and use of PI-based or non-standard ART regimens.

12 January 2016 in Global Health Action
Verified
Journal Article
Open access
SWSten Wilhelmson
Sten Wilhelmson
ARAnton Reepalu
Anton Reepalu
TBTaye Tolera Balcha
Taye Tolera Balcha
GJGodana Jarso
Godana Jarso
PBPer Björkman
Per Björkman
BackgroundAccess to second-line antiretroviral therapy (ART) for HIV-positive patients remains limited in sub-Saharan Africa. Furthermore, outcomes of second-line ART may be compromised by mortality and loss to follow-up (LTFU).ObjectiveTo determine retention in care among patients receiving second-line ART in a public hospital in Ethiopia, and to investigate factors associated with LTFU among adults and adolescents.DesignHIV-positive persons with documented change of first-line ART to a second-line regimen were retrospectively identified from hospital registers, and data were collected at the time of treatment change and subsequent clinic visits. Baseline variables for adults and adolescents were analyzed using multivariate Cox proportional hazards models comparing subjects remaining in care and those LTFU (defined as a missed appointment of ≥90 days).ResultsA total of 383 persons had started second-line ART (330 adults/adolescents; 53 children) and were followed for a median of 22.2 months (the total fo...